Thalidomide-based TNF-α inhibitors for neurodegenerative diseases

Acta Neurobiologiae Experimentalis

Volumn 64, Issue 1, 2004, Pages 1-9

  Greig, Nigel H ^a   Giordano, Tony ^b   Zhu, Xiaoxiang ^a   Yu, Qian Sheng ^a   Perry, Tracy Ann ^a   Holloway, Harold W ^a   Brossi, Arnold ^c   Rogers, Jack T ^d   Sambamurti, Kumar ^e   Lahiri, Debomoy K ^f  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid peptide; Erythema nodosum leprosum (ENL); Lipopolysacharide (LPS); Peripheral blood mononuclear cells (PBMC); Rheumatoid arthritis; Thalidomide; Thalidomide analogues; TNF inhibitors

Indexed keywords

ETANERCEPT; INFLIXIMAB; LIPOPOLYSACCHARIDE; LUCIFERASE; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; INFLAMMATION; LIPOPHILICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; RNA STABILITY; RNA TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE;

CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEURODEGENERATIVE DISEASES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144358504     PISSN: 00651400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2002) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
2. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiat 25: 1341-1357.
3. Bakheet T, Frevel M, Williams BRG, Greer W, Khabar KSA (2001) ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res 29: 246-254.
4. Bales KR, Du Y, Holtzman D, Cordell B, Paul SM (2000) Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging 21: 427-432. (discussion: 451-453.)
5. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharm 55: 1827-1834.
6. Begg AA, Baltimore D (1996) An essential role of NFκ3 in preventing TNF-α-induced cell death. Science 274: 782-784.
7. Bhattacharya S, Giordano T, Brewer G, Malter JS (1999) Identification of AUF-1 ligands reveals vast diversity of early response gene mRNAS. Nucl Acids Res 27: 1464-1472.
8. Breitner JCS (1997) Inflammatory processes and anti-inflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 17: 789-794.
9. Brennan CM, Steitz JA (2001) HuR and mRNA stability. Cell Mol Life Sci 58: 266-277.
10. Buxbaum JD, Oishi M, Chen HI, Pankas-Kramarski R, Jaffe EA, Grandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1: 10075-10078.
11. Burton T, Liang B, Dibrov A, Amara F (2002) Transforming growth factor-α-induced transcription of the Alzheimer β-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads. Biochem Biophys Res Commun 295: 713-723.
12. Carballo E, Lai WS, Blackshear P (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001-1005.
13. Cava MP, Levinson MI (1985) Thionation reaction of Lawesson's reagents. Tetrahedron 41: 5061-5087.
14. Chen C-YA, Shyu A-B (1995) Au-rich elements: characterization and importance in mRNA degradation. TIBS 20: 465-470.
15. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide in an inhibitor of angiogenesis. Proc Natl Acad Sc U S A 91: 34082-34085.
16. Das S, Potter H (1995) Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron 4: 447-456.
17. Dean JLE, Wait R, Mahtani KR, Sully G, Clark AR, Saklatvala J (2001) The 3' untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol Cell Biol 21: 721-730.
18. Derynck R, Zhang Y, Feng XH (1998) Smads: transcriptional activators of TGF-β responses. Cell 95: 737-740.
19. Eger K, Jalalian M, Verspohl EJ, Lupke NP (1990) Synthesis, central nervous system activity and teratogenicity of a homothalidomide. Arzneimittelforschung 40: 1073-1075.
20. Fan XC, Steitz JA (1998) Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAS. EMBO J 17: 3448-3460.
21. Ford L, Watson J, Keene JD, Wilusz J (1999) ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system. Genes Dev 13: 188-201.
22. Fujita J, Mestre JR, Zeldis K, Subbaramaiah K, Dannenberg AJ (2001) Thalidomide and its analogues inhibit lipopolysacharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7: 3349-3355.
23. Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, Okeda R, Ihara Y (1998) Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol 152: 983-92.
24. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC (1989) Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 86: 7606-7610.
25. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LT, White CL 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86: 7611-7615.
26. Han J, Brown T, Beutler B (1990) Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171: 465-475.
27. Haslett P, Corral L, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Expl Med 187: 1885-1889.
28. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387-398.
29. Kruys V, Huez G (1994) Translational control of cytokine expression by 3'AU-rich sequences. Biochemie 76: 862-866.
30. Kruys V, Marinx O, Shaw G, Deschamps J, Huez G (1989) Translational blockade imposed by cytokine-derived UA-rich sequences. Science 245: 852-855.
31. Kumar S, Witzig TE, Rajkumar SV (2002) Thalidomide as an anti-cancer agent. J Cell Mol Med 6: 160-174.
32. Lahiri DK, Ge Y (2000) Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue. Brain Res Brain Res Protoc 5: 257-265.
33. Lahiri DK, Nall C (1995) Promoter activity of the gene encoding the β-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res 32: 233-240.
34. Lahiri, D.K., Farlow, M.R., Greig, N.H., Sambamurti, K. (2002) Current drug targets for Alzheimer's disease treatment. Drug Dev Res 56: 267-281.
35. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, Rogers JT (2003a) Role of cytokines in the gene expression of amyloid β-protein precursor: Identification of a 5'-UTR-Binding nuclear factor and its implications in Alzheimer's disease. J Alz Dis 5: 81-90.
36. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS (2003b) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4: 97-112.
37. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19: 4311-4323.
38. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22: 799-809.
39. Meierhofer C, Wiedermann CJ (2003) New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel 6: 92-99.
40. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177: 1675-1680.
41. Mrak RE, Griffin WS (2001) Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22: 903-908.
42. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304-307.
43. Price DK, Ando Y, Kruger E, Weiss M, Figg WD (2002) 5′ -OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monitoring 24: 104-110.
44. Richardson P, Hideshima T, Anderson K (2002) Thalidomide: emerging role in cancer medicine. Annu Rev Med 53: 628-657.
45. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN (1999) Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274: 6421-6431.
46. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002a) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528.
47. Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig NH, Sarang SS, Gullans SR (2002b) Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci 19: 77-82.
48. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1: 1-31.
49. Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor of a production by stimulated human monocytes. J Exp Med 173: 699-703.
50. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN (1993) The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168: 408-414.
51. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
52. Shaw KT, Utsuki T, Rogers J, Yu Q-S, Sambamurti K, Brossi A, Ge Y-W, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta-amyloid precursor mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98: 7605-7610.
53. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD (2000) Tranforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stablization of mRNA. J Biol Chem 275: 6628-6635.
54. Sheskin J (1965) Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 6: 303-310
55. Thanos D, Maniatis T (1995) NFκB: a lesson in family values. Cell 80: 529-532.
56. Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl J Med 345: 1515-1521.
57. Weninger SC, Yankner BA (2001) Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 7: 527-528.
58. Wilson GM, Sutphen K, Moutafis M, Sinha S, Brewer G (2001) Structural remodeling of an A+U-rich RNA element by cation or AUF1 binding. J Biol Chem 276: 38400-38409.
59. Xu NH, Chen CA, Shyu A-B (1997) Modulation of the fate of cytoplasmic mRNA by AU-rich elements: Key sequence features controlling mRNA deadenylation and decay. Mol Cell Biol 17: 4611-4621.
60. Xu N, Chen CA, Shyu A-B (2001) Versatile role for hnRNP D isoforms in the differential regulation of cytoplasmic mRNA turnover. Mol Cell Biol 21: 6960-6971.
61. Zandi PP, Breitner JC (2001) Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22: 811-817.
62. Zhu XX, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, Brossi A, Greig NH (2003) Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem 46: 5222-5229
63. Żekanowski C, Religa D, Graff C, Filipek S, Kuźnicki J (2004) Genetic aspects of Alzheimer's disease. Acta Neurobiol Exp (Wars) 64: 19-31.